Sloan et al. reported that the odds of decreased vision (defined as decline from normal to moderate, moderate to severe, or severe to blindness, where moderate, severe, and blindness is defined according to the International Classification of Diseases, Ninth Revision, Clinical Modification code) fell by 41% after introduction of anti-VEGF therapy (odds ratio, 0.59; 95% confidence interval, 0.52–0.68) [23]. This evidence concerns the gene VEGFA and blindness (disorder).